08/29/2026
🚨 Women’s Health Needs Your Voice 🚨
The FDA is holding a public meeting on Testosterone Use in Menopausal Women to discuss the science, benefits, risks, and future of testosterone therapy for women. Public comments are being accepted, and this is our opportunity to be heard. 
For too long, women have lacked:
✅ FDA-approved testosterone formulations designed specifically for women�✅ Access beyond the narrow indication of HSDD (Hypoactive Sexual Desire Disorder)�✅ Recognition of testosterone’s potential impact on sexual health, cognition, mood, energy, muscle health, and overall quality of life�✅ Equitable access compared with available testosterone products for men
We are urging women, clinicians, researchers, and advocates to submit public comments asking the FDA to:
🔹 Support development and approval of testosterone products formulated specifically for women�🔹 Expand research into the full range of clinical uses for testosterone in women, not just HSDD�🔹 Reevaluate barriers that limit access to appropriate testosterone therapy�🔹 Work with appropriate agencies to reconsider the classification of testosterone as a controlled substance when used therapeutically
Every story matters. Share your experience, your challenges accessing care, and the impact testosterone has had on your health and well-being.
📢 Submit your public comment before the docket closes. The FDA has opened a public docket on testosterone use in menopausal women and comments are being accepted through October 19, 2026. 
The Food and Drug Administration's (FDA) Office of Women's Health and the Center for Drug Evaluation and Research are announcing a public workshop titled "Testosterone Use in Menopausal Women." The purpose of the public workshop is to examine the current scientific evidence and critical knowledge...